168 related articles for article (PubMed ID: 25562146)
21. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):686-691. PubMed ID: 30201068
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer.
Hsu SC; Hung TH; Wang CW; Ng KF; Chen TC
Pathol Int; 2015 May; 65(5):231-9. PubMed ID: 25708242
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
Fiset PO; Labbé C; Young K; Craddock KJ; Smith AC; Tanguay J; Pintilie M; Wang R; Torlakovic E; Cheung C; da Cunha Santos G; Ko HM; Boerner SL; Hwang DM; Leighl NB; Tsao MS
Cancer; 2019 Nov; 125(22):4043-4051. PubMed ID: 31390053
[TBL] [Abstract][Full Text] [Related]
25. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
26. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
[TBL] [Abstract][Full Text] [Related]
27. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S; Takeuchi S; Nakagawa T; Yamada T
Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
[TBL] [Abstract][Full Text] [Related]
28. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
29. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
Schink JC; Trosman JR; Weldon CB; Siziopikou KP; Tsongalis GJ; Rademaker AW; Patel JD; Benson AB; Perez EA; Gradishar WJ
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217578
[TBL] [Abstract][Full Text] [Related]
30. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
31. Update on emerging biomarkers in lung cancer.
Bernicker EH; Allen TC; Cagle PT
J Thorac Dis; 2019 Jan; 11(Suppl 1):S81-S88. PubMed ID: 30775031
[TBL] [Abstract][Full Text] [Related]
32. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
33. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
34. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
J Thorac Oncol; 2013 Jul; 8(7):823-59. PubMed ID: 23552377
[TBL] [Abstract][Full Text] [Related]
35. Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
Soni S; Rastogi A; Prasad KT; Behera D; Singh N
Lung Cancer; 2021 Jan; 151():16-19. PubMed ID: 33278669
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
37. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
38. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
39. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology
J Mol Diagn; 2013 Jul; 15(4):415-53. PubMed ID: 23562183
[TBL] [Abstract][Full Text] [Related]
40. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
